1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Urologix, Inc.

Urologix, Inc.

ULGX
Urologix, Inc.US flagOther OTC
0.00
USD
- -
- -
2,182.00Market Cap
Urologix, Inc.
ULGX
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
TTM
FRC
0.54
0.71
1.2
1.65
1.35
1.74
1.81
1.81
1.49
1.04
0.89
1.02
0.86
1.16
0.8
0.67
0.56
Revenue per Share
-1.24
-0.62
-0.4
-0.12
-0.74
0.03
0.2
0.38
-0.92
-1.04
-0.31
-0.15
-0.26
-0.32
-0.21
-0.36
-0.22
Basic EPS, GAAP
-0.76
-0.42
-0.36
-0.21
-0.56
0.2
0.2
0.01
0.08
-0.09
-0.28
-0.09
-0.18
-0.05
-0.1
-0.07
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-4.91
-5.45
-5.32
-5.04
-5.72
-5.69
-5.39
-4.99
-5.91
-6.94
-7.19
-7.32
-7.55
-7.77
-5.74
-5.96
-5.9
Book Value per Share
3.13
2.5
1.5
1.37
0.7
0.8
1.06
1.59
1.21
0.95
0.68
0.56
0.33
-0.32
-0.2
-0.39
-0.43
Tangible Book Value per Share
11
12
13
14
14
14
14
14
14
14
14
15
15
15
21
21
22
Basic Weighted Avg Shares
6
8
15
23
19
24
26
26
21
15
13
15
13
17
17
14
12
Sales/Revenue/Turnover
-259.02
-105.03
-38.35
-8.29
-47.38
1.58
12.1
2.97
-41.9
-112.69
-34.84
-15.28
-29.64
-24.34
-27.31
-28.09
-8.24
Operating Margin (%)
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
Depreciation Expense
-14
-7
-5
-2
-10
- -
3
5
-13
-15
-4
-2
-4
-5
-4
-8
-5
Net Income, GAAP
- -
- -
- -
- -
2.85
44.55
13
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-231.15
-86.95
-33.48
-7.26
-55.04
1.46
10.99
21.22
-62.1
-99.94
-34.48
-14.68
-29.7
-27.57
-25.87
-53.45
-38.29
Profit Margin (%)
29
23
15
14
4
9
13
17
16
11
8
7
4
-2
3
-1
-3
Working Capital
- -
- -
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5
5
4
LT Debt
36
29
40
39
29
30
33
40
28
14
10
8
5
1
- -
-7
-8
Total Equity
- -
- -
- -
- -
-24.55
0.71
8.6
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
14.08
-0.45
-3.62
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'15
Dec'15
Mar'15
ST Debt
1
1
2
LT Borrowings
5
5
4
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
2
2
2

Working Capital

FRC

•

in mil. unless spec.
Sep'15
Dec'15
Mar'15
Total Current Assets
4
4
3
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
2
1
1
Inventories
1
1
1
Total Current Liabilities
4
5
6
Payables & Accruals
2
2
2
ST Debt
1
1
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-201.68%
-387.89%
-1,761.19%
Free Cash Flow
47.94%
20.9%
-24.06%
Net Income, GAAP
50.75%
23.13%
77.26%
Sales/Revenue/Turnover
-3.63%
3.81%
-14.2%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
4
4
4
4
17
2014
4
4
3
3
14
2015
3
3
3
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
-0.05
-0.05
-0.05
-0.06
-0.21
2014
-0.06
-0.05
-0.08
-0.17
-0.36
2015
-0.02
-0.02
-0.02
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
Similar Companies
Rainmed Medical Limited (2297.HK)
Double Medical Technology Inc. (002901.SZ)
Varex Imaging Corporation (VREX)
Lucira Health, Inc. (LHDX)
Alphatec Holdings, Inc. (ATEC)
Micro Imaging Technology, Inc. (MMTC)
Business
Urologix, Inc. (ULGX) develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy (CTT), which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort; and Prostiva RF Therapy System, which delivers radio frequency energy directly into the prostate to destroy excess tissue, reduce urethral constriction, and relieve BPH symptoms. Urologix, LLC serves urologists and patients seeking office-based alternatives to medication or surgery, with operations focused on the U.S. market. Founded in 1991 and headquartered in Minneapolis, Minnesota, the company emphasizes safe, durable in-office therapies that demonstrate long-term efficacy, including symptom score and flow rate improvements in over 90% of CTT patients and 86% of Prostiva patients through five years. In 2016, Urologix sold most operating assets to a private buyer to settle debt with Medtronic, transitioning to private ownership as Urologix, LLC while retaining Plymouth, Minnesota operations and continuing to provide Cooled ThermoTherapy and Prostiva RF Therapy without customer disruption; no major acquisitions, funding rounds, partnerships, or product launches have been reported since.